Press Releases
March 25, 2025
Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development
Cytonics Seeks $24 million to pursue FDA Phase 2 Clinical Study of CYT-108, the Company's Novel Therapy for Osteoarthritis